Previous 10 | Next 10 |
home / stock / bmymp / bmymp news
An internationally weighted portfolio will inevitably have a dividend payout weighting favoring the months of March, April, and May (as well as November/October/September, usually). This is because many international/European stocks have annual or bi-annual payouts centered around mon...
Trial data is supportive of an EUA: Leronlimab outperformed every approved or recommended drug in critically ill patients. Shorts have a flawed analysis that doesn’t correct for patient age distribution. The clinical outcome of length of hospitalization was statistical...
Connect Biopharma has filed proposed terms for its U.S. IPO. The firm is developing antibody-based treatments for inflammatory diseases. While the IPO isn't cheap, CNTB has seen promising Phase 2 trial efficacy results and the IPO is worth a close look for life science investors. ...
Bristol-Myers Squibb Company (BMY) Barclays Global Healthcare Conference March 09, 2021 03:00 PM ET Company Participants David Elkins - CFO Conference Call Participants Carter Gould - Barclays Presentation Carter Gould Okay. Good afternoon. My name is Carter Gould. I am senior analyst here at...
Bristol-Myers terminated the contingent value right related to the Celgene merger. The right is related to the approval of three separate drugs. 2/3 drugs have been approved and the final is one likely to get approved. The second approval arrived a little over a month late, ca...
Bristol-Myers Squibb Co. (BMY) Cowen Virtual 41st Annual Health Care Conference Call March 03, 2021, 10:20 AM ET Company Participants Samit Hirawat - Executive Vice President and Chief Medical Officer Conference Call Participants Stephen Scala - Cowen and Company Presentation Stephen Scala Go...
Bristol-Myers Squibb Co (BMY) 42nd Annual Raymond James Institutional Investor Conference March 02, 2021 08:20 AM ET Company Participants David Elkins - Executive Vice President, Chief Financial Officer Conference Call Participants Dane Leone - Raymond James Presentation Dane Leone Greetings,...
CRSR is one of the few companies that hold a patent to the 2020 Nobel Prize CRISPR technology. The company's pipeline includes potential blockbuster medicines, demonstrating a more aggressive strategy compared to Editas Medicine, one of its main competitors. The recent correction ...
2020 was a volatile year in the market, leading to multiple dividend cuts in the portfolio. Despite those cuts, income grew by ten percent, meeting my targeted goal. Recent dividend increases from Abbott Labs, Broadcom, and Amgen put the portfolio on course for continued success. ...
Prometheus Biosciences has filed to raise $125 million in a U.S IPO. The firm is developing treatments for inflammatory bowel disease conditions. RXDX is in Phase 1 safety trials for its lead candidate for the treatment of ulcerative colitis and Crohn's disease. For further ...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb $2Pr Company Name:
BMYMP Stock Symbol:
OTCMKTS Market:
Bristol-Myers Squibb $2Pr Website: